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In Brief
Development of late-onset, sporadic
Alzheimer’s disease (SAD) has been
linked with a range of genetic loci, but
determining how variants within these
loci contribute to disease progression
remains challenging. Using hIPSC-
derived neurons from SAD patients and
controls, Young et al. link risk and
protective variants in the SORL1 gene, an
SAD-associated locus, with BDNF-
sensitive SORL1 expression, APP
processing, and control of amyloid b
production.
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Predisposition to sporadic Alzheimer’s disease
(SAD) involves interactions between a person’s
unique combination of genetic variants and the envi-
ronment. The molecular effect of these variants may
be subtle and difficult to analyze with standard
in vitro or in vivo models. Here we used hIPSCs to
examine genetic variation in the SORL1 gene and
possible contributions to SAD-related phenotypes
in human neurons. We found that human neu-
rons carrying SORL1 variants associated with an
increased SAD risk show a reduced response to
treatment with BDNF, at the level of both SORL1
expression and APP processing. shRNA knockdown
of SORL1 demonstrates that the differences in
BDNF-induced APP processing between genotypes
are dependent on SORL1 expression. We propose
that the variation in SORL1 expression induction by
BDNF is modulated by common genetic variants
and can explain how genetic variation in this one
locus can contribute to an individual’s risk of
developing SAD.
INTRODUCTION
Late-onset, sporadic Alzheimer’s disease (SAD) is the most
common cause of neurodegeneration in the elderly. SAD is a hu-
man disorder in which individual patients might develop disease
differently because of a poorly understood collaboration of mul-
tiple genetic risk factors and the environment. In fact, although
no genes have been identified that cause SAD, as much as
60%–80% of risk for developing SAD may be genetic (Gatz
et al., 2006). Although hundreds of genetic associations with
SAD have been reported (Bertram et al., 2007), many of these re-
ported associations are based on small samples or have not
been replicated independently, and large-scale meta-analyses
pooling multiple genome-wide association studies (GWASs)
found only 20 or so loci to be associated consistently with the
risk of developing SAD (Bertram et al., 2007; Chouraki and Se-shadri, 2014). Although many associated genes are seemingly
random, it is possible to group some of the top hits into genes
involved in specific cellular pathways, such as endocytosis,
cholesterol metabolism, and immune function (Olgiati et al.,
2011). At present, many attempts to measure phenotypes attrib-
uted to SAD-associated genes have used post-mortem material
because of the inaccessibility of brain tissue in living subjects
(Cruchaga et al., 2014; Griciuc et al., 2013; Holton et al., 2013;
Karch et al., 2012). These studies have yielded mixed results,
perhaps because the effects on individual cells aremasked in tis-
sues composed ofmultiple cell types. It has also been suggested
that different variants may control gene response to damage or
to normal signaling in the brain rather than controlling basal
levels, highlighting the importance of studies in living humanma-
terial (Holton et al., 2013).
To date, several studies have consistently generated valid hu-
man induced pluripotent stem cell (hIPSC)models of Alzheimer’s
disease (AD) primarily from fibroblasts of patients with rare,
early-onset familial AD (FAD) mutations (reviewed in Cao et al.,
2014; Goldstein et al., 2015). In general, these models have
fairly accurately represented disease phenotypes regarding
increased detection of amyloid b (Ab) peptides, increases in
the Ab42:40 ratio, increased phosphorylation of Tau protein,
and the presence of enlarged endosomes. However, strikingly
fewer papers have so far modeled SAD, which accounts
forR95% of all clinical cases. Two recent studies have reported
hIPSC lines from SAD patients (Israel et al., 2012; Kondo et al.,
2013). Interestingly, in each case, only one of the two hIPSC-
derived neuronal samples demonstrated phenotypes consistent
with FAD lines. This variability speaks to the complexity of
each human genetic background and its influence on disease
causation and progression.
To begin to address these issues, we generated and analyzed
a random cohort of 13 hIPSC lines derived from SAD patients
and controls from the University of California, San Diego
(UCSD) Shiley-Marcos Alzheimer’s Disease Research Center
(ADRC). Using purified neurons made from these hIPSC lines,
we focused on the SORL1 gene, which encodes an endocytic
trafficking factor whose levels modulate the processing of amy-
loid precursor protein (APP) to Ab and other proteolytic products
implicated in SAD (Andersen et al., 2005). Loss of SORL1
expression has been documented in SAD cases (Dodson et al.,
2006; Scherzer et al., 2004), and the SORL1 locus has beenCell Stem Cell 16, 373–385, April 2, 2015 ª2015 Elsevier Inc. 373
associated with SAD in both candidate gene and GWAS ana-
lyses (Bettens et al., 2008; Lambert et al., 2013; Lee et al.,
2007; Reitz et al., 2011; Rogaeva et al., 2007). Despite these find-
ings, it is currently unknown how expression of SORL1 is lost in
SAD and how common variants in the SORL1 gene contribute to
expression regulation.
We report that, in hIPSC-derived purified human neurons,
basal levels of SORL1 expression are highly variable but that
we can consistently induce SORL1 expression above the base-
line and reduce levels of Ab using neurotrophic and intracellular
signaling molecules. Moreover, SORL1 expression induction
and the decrease of Ab in response to neurotrophin treatment
is highly correlated with a common genotypic risk variant at
the 50 end of SORL1 (minor allele frequency = 0.42), suggesting
that common variants in this region control this signaling
response. Interestingly, we found that this phenotype is indepen-
dent of whether neurons were derived from SAD patients or con-
trols and that manipulation of SORL1 expression (by knockdown
or overexpression) directly regulates the amount of Ab peptides
secreted by hIPSC-derived human neurons. These experiments,
along with previous work in other models (Caglayan et al., 2014),
confirm the importance of the SORL1/APP pathway in SAD and
highlight hIPSC technology as a novel way to test the role of
human genomic variants in complex disease.
RESULTS
Basal Levels of SORL1 Expression Are Variable in
Human NSCs and Neurons Derived from hIPSCs
Reduced SORL1 expression has been reported in SAD patient
lymphoblasts and cerebrospinal fluid and in post-mortem ana-
lyses (Dodson et al., 2006; Ma et al., 2009; Scherzer et al.,
2004). We had access to 22 fibroblast samples (10 non-
demented controls [NDCs] and 12 probable SAD cases clinically
diagnosed byNational Institute of Neurological andCommunica-
tive Disorders and Stroke-Alzheimer’s Disease and Related Dis-
orders Association (NINCDS-ADRDA) (McKhann et al., 1984))
from the UCSD ADRC (Figure 1A and Table 1). Our laboratory
has also reprogrammed fibroblasts derived from J. Craig Venter
(J.C.V.) (Gore et al., 2011; Woodruff et al., 2013), whose diploid
genome sequence has been published and is known to carry
genomic variants in SORL1 associated with SAD (Levy et al.,
2007). Cellular phenotypes of genomic risk variants may be diffi-
cult to detect in post-mortem tissue, which is often a mix of cell
types taken at the end stage of a diseased brain. We hypothe-
sized that a culture of purified human neurons containing the
endogenous genome of an individual might provide a more sen-
sitive system to detect potentially subtle phenotypes. Therefore,
to ask whether SORL1 genomic variants affect basal expression
at levels detectable in hIPSC-derived neurons, we first geno-
typed our small fibroblast cohort for variants in SORL1 docu-
mented previously to be associated with risk (R) or protection
(P) from AD (Rogaeva et al., 2007). Next we reprogrammed a
random subset of these fibroblasts, established hIPSC lines,
differentiated neural stem cell (NSC) lines, and purified neurons
from these individuals following standard protocols (Israel
et al., 2012; Yuan et al., 2011; Table 1; Figure S1A). All of the
hIPSC lines used in this study are euploid and can differentiate
into the three germ layers: endoderm, mesoderm, and ectoderm374 Cell Stem Cell 16, 373–385, April 2, 2015 ª2015 Elsevier Inc.(Table S1). Human neurons differentiated and purified using this
protocol are a mix of glutamatergic, GABAergic, and cholinergic
subtypes and are electrophysiologically active (Israel et al.,
2012).
Two common haplotypes in the SORL1 locus have been asso-
ciated with SAD risk in multiple studies, one defined by a set of
SNPs in strong linkage disequilibrium (LD) at the 50 end of the
gene and one defined by a set of SNPs in LD at the 30 end of
the gene (Rogaeva et al., 2007). Multiple studies have confirmed
a strong linkage disequilibrium in these regions using various
population datasets (Bettens et al., 2008; Rogaeva et al., 2007;
Wen et al., 2013). We genotyped our fibroblast lines for eight
representative SORL1 variants, four SNPs in the 50 region and
four SNPs in the 30 region. For clarity, we utilized the names of
these SNPs as assigned by Rogaeva et al. (2007): SNPs 4, 8,
9, and 10 at the 50 end and SNPs 22, 23, 24, and 25 at the 30
end of SORL1 (Figure 1B; Figure S1). We also queried publicly
available data from phase I of the 1000 Genomes Project (1000
Genomes Project Consortium et al., 2012) focusing on the
Centre d’Etude du Polymorphisme Humain population, which
closely resembles the population of fibroblast donors from the
ADRC (northern and western European populations) to confirm
the extent of disequilibrium at these sites (Figure 1B). Three of
the SNPs at the 50 end of SORL1 (SNPs 8, 9, and 10) in our 23
fibroblast samples showed apparent complete LD (the SNPs
were found together in all unambiguous homozygous samples,
and the estimated pairwise R2 was 1.0; Figure 1C; Figure S1C).
The same pattern of LD was observed in our analysis of the
1000 Genomes data (pairwise R2 = 1.0; Figure 1B). LD was not
as strong at the 30 end of SORL1 in our sample (Figure 1D; Fig-
ure S1C) or in the public data, where the pairwise R2 ranged
from 0.64–0.88 (Figure 1B). There was little association between
the 30 haplotypes and cellular phenotypes in preliminary experi-
ments (Figure S3), and, therefore, we focused our attention on
the 50 haplotype. We designated the haplotype at the 50 end
comprised by SNPs 8, 9, and 10 as either R (risk) or P (protective)
based on previous association studies (Reitz et al., 2011; Ro-
gaeva et al., 2007) and classified our patient samples as P/P,
R/P, or R/R. That is, R/R patients are homozygous for the vari-
ants at SNPs 8, 9, and 10, which have been reported to be asso-
ciated with an increased risk of developing SAD; P/P patients are
homozygous for alleles at SNPs 8, 9, and 10, associated with a
reduced SAD risk; and R/P patients are heterozygous for risk
and protective SNPs. Interestingly, previous work using post-
mortem brain tissue has implicated the 50 region of SORL1 in
alternative splicing and reduced SORL1 expression in the tem-
poral cortex, although the functional variants have not been iden-
tified (Grear et al., 2009; McCarthy et al., 2012). Therefore, we
hypothesized that hIPSC-derived neurons with risk haplotypes
in this 50 region may show differential SORL1 expression.
We analyzed the levels of SORL1mRNA in NSC lines and neu-
rons differentiated and purified from NSC lines (six NDC ge-
nomes, including J.C.V., and seven SAD genomes). At the basal
level, we found a highly variable expression of SORL1 in all cell
types and genotypes (P/P, R/P, and R/R) with no detectable dif-
ferences in SORL1 expression because of disease state (NDC
versus AD) or SORL1 haplotype (Figures 2A–2D). We also
analyzed the parent fibroblast lines for basal levels of SORL1
gene expression and, similarly, found no differences between
Figure 1. 50 SNPs in the SORL1 Gene Comprise a Haplotype in Strong LD
(A) Diagram of the experimental design and cell lines. See also Tables 1 and S1.
(B) Representative diagram of the SORL1 gene and LD structure of the 50 haplotype and 30 haplotype in SORL1: SNPs 4, 7, 8, 9, 10, and 11 and SNPs 22, 23, 24,
and 25, generated from the 1000 Genomes project, Phase I. R2 correlation values are indicated on the LD plot and color-coded in the underlying squares.
R2 values of 1 indicate complete linkage. See also Figure S1C.
(C) 23 patient fibroblast samples were genotyped for four SNPs (SNP4, SNP8, SNP9, and SNP10) at the 50end of SORL1 identified in Rogaeva et al. (2007) as
being associated with AD. The percentage of individuals with homozygous risk SNPs at positions 8, 9, and 10 were identical, consistent with the previously
reported strong LD of these SNPs.
(D) Fibroblast samples from the same patient group were genotyped for four SNPs (SNP22, SNP23, SNP24, and SNP25) at the 30 end of SORL1 also identified in
Rogaeva et al. (2007) as being associated with AD. In these samples, the percentage of individuals with risk SNPs at these positions was not identical, suggesting
a lack of a clear haplotype at the 30 end in this sample set.
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Table 1. Cell Lines Used in This Study
UCSD ADRC No. Name SORL1 50 Genotype Diagnosis Cell Type Analyzed Reference
8149 SAD1 R/R probable SAD fib, NSC, neuron Israel et al., 2012
3093 SAD2 P/P probable SAD fib, NSC, neuron Israel et al., 2012
2991 SAD3 R/R probable SADa fib, NSC, neuron
3121 SAD4 R/P probable SAD fib, NSC, neuron
3158 SAD5 R/P probable SAD fib, NSC, neuron
8097 SAD6 P/P probable SAD fib, NSC, neuron
2800 SAD7 R/P probable SAD fib, NSC, neuron
3053 FIB3053 P/P probable SAD fibb
8094 FIB8094 R/R probable SAD fibb
3131 FIB3131 R/R probable SAD fibb
8020 FIB8020 R/R probable SAD fibb
654 FIB654 R/R probable SAD fibb
3113 FIB3113 R/R probable SAD fibb
27 NDC1 R/P NDC fib, NSC, neuron Israel et al., 2012
8011 NDC2 R/R NDC fib, NSC, neuron Israel et al., 2012
14096 NDC3 R/P NDC fib, NSC, neuron
40 NDC4 R/P NDC fib, NSC, neuron
8078 NDC5 P/P NDC fib, NSC, neuron
J.C.V. J.C.V. R/R NDC fib, NSC, neuron Gore et al., 2011; Woodruff et al., 2013
2608 FIB2608 P/P NDC fibb
2785 FIB2785 P/P NDC fibb
8072 FIB8072 P/P NDC fibb
8150 FIB8150 R/P NDC fibb
P/P = protective haplotype at 50end of SORL1 (SNPs 8, 9, and 10); R/P, heterozygous risk/protective haplotype; R/R, risk haplotype; fib, fibroblast.
aPatient SAD3was diagnosed as having probable AD during the course of this study and prior to death. This patient passed away while this manuscript
was in preparation, and post-mortem pathology has revealed a diagnosis of tangle-predominant dementia with hippocampal sclerosis rather than AD.
However, the statistically significant findings presented in this manuscript are only related to SORL1 genotypes and not to whether patients are diag-
nosed as NDC or SAD. Therefore, we still included hIPSC-derived cell lines from patient SAD3 in our results.
bThe fibroblast line was not reprogrammed.genotypes or disease states in these cells (Figures S2A and S2B)
We did see a significant increase in SORL1 expression upon dif-
ferentiation to NSCs and neurons (Figure S2C), consistent with
previous reports showing that SORL1 is highly expressed in
the CNS (Mo¨rwald et al., 1997; Motoi et al., 1999).
A SORL1 Haplotype Associated with Protection from AD
May Regulate the Induction of SORL1 Expression by
Certain Growth and Neurotrophic Factors
Our neuronal differentiation protocol contains a mix of growth
and neurotrophic factors (Yuan et al., 2011) including brain-
derived neurotrophic factor (BDNF), which can induce the mu-
rine homolog of SORL1 (LR11) (Rohe et al., 2009), and cyclic
AMP (cAMP), which can be elevated by BDNF treatment (Cheng
et al., 2011). BDNF has been hypothesized to be protective in
various animal models of AD, and loss of BDNF has been impli-
cated in AD (Nagahara et al., 2009). Treatments that increase
intracellular cAMP levels, such as liraglutide, have also been
shown to be protective in AD models (Hunter and Ho¨lscher,
2012; Parthsarathy and Ho¨lscher, 2013). Therefore, we tested
the acute effects of these two factors, BDNF and cAMP, on
SORL1 expression in purified human neurons. Although several
growth and neurotrophic factors were present in our neuronal376 Cell Stem Cell 16, 373–385, April 2, 2015 ª2015 Elsevier Inc.media (Israel et al., 2012; Yuan et al., 2011), we induced
SORL1 expression above the baseline in our system by acutely
treating neurons with additional, exogenous BDNF or cAMP for
24 hr.
We measured SORL1 expression induction by quantitative
RT-PCR (qRT-PCR) and found that, averaging across neurons
derived from our 13 cell lines, the absolute relative expression
level for BDNF-treated neurons was not significantly different
from that of untreated neurons (Figure 3A). However, we consis-
tently noticed that neurons from 9 of the 13 patients exhibited a
significant induction of SORL1 expression above the baseline in
response to BDNF, whereas neurons from 4 of the 13 patients
did not (Figure 3B; Table 2). When we examined the cell line
response to BDNF by genotype, we found that all four of the lines
in which SORL1 was not induced by BDNF were homozygous
R/R, whereas all lines with a P allele did respond to BDNF treat-
ment (Figure 3C, post hoc Fisher’s exact test, p = 0.001; Table 2).
This suggests that the P haplotype is a marker for a dominant
protective genetic variant. Available SAD case control data are
highly consistent with a dominant protective variant (Table S2).
A pooled analysis of public genotype data of 1,640 SAD cases
and 1,728 controls with a similar ethnic background as our series
suggests a consistent protective effect of the R/P and P/P
Figure 2. Basal Levels of SORL1 mRNA Are
Variable in NSCs and Purified Human Neu-
rons and Do Not Correlate with a Diagnosis
of Probable SAD or NDC or with the Pres-
ence of SORL1 R and P Genotypes
(A) qRT-PCR analysis of basal SORL1 expression
in 13 NSC lines. No significant difference was
detected related to the disease state, NDC versus
AD. Statistics: Mann-Whitney test; NDC versus
AD, p = 0.63; NDC, n = 6; AD, n = 7. See also
Figure S2A.
(B) qRT-PCR analysis of basal SORL1 expression
in purified neurons made from 13 NSC lines. No
significant difference was detected related to the
disease state, NDC versus AD. Statistics: Mann-
Whitney test; NDC versus AD, p = 0.8; NDC, n = 6;
SAD, n = 7. See also Figure S2A.
(C) qRT-PCR analysis of basal SORL1 expression
in 13 NSC lines. No significant difference was
detected related to the SORL1 R or P haplo-
type. Statistics: Kruskal-Wallis test was used to
compare P/P versus R/P versus R/R (p = 0.56; P/P,
n = 3; R/P, n = 6; R/R, n = 4). See also Figure S2B.
(D) qRT-PCR analysis of basal SORL1 expression
in purified neurons made from 13 NSC lines. No
significant difference was detected related to the
SORL1 R or P haplotype. Statistics: Kruskal-Wallis
test was used to compare P/P versus R/P versus
R/R (p = 0.35; P/P, n = 3; R/P, n = 6; R/R, n = 4).
See also Figure S2B.
All error bars are SD.haplotypes relative to the R/R haplotype, with an odds ratio of
0.77 (95% confidence interval [CI], 0.66–0.90) for R/P versus
R/R haplotypes, an identical odds ratio (OR) of 0.77 (95% CI,
0.63–0.93) for P/P versus R/R haplotypes, and an OR of 0.99
(95% CI, 0.82–1.20) for R/P versus P/P haplotypes. The sample
size was not sufficient to formally compare SORL1 expression in
response to BDNF across all three haplotypes in our cell lines.
However, induction in R/P cell lines was similar to induction in
P/P cell lines, and mean induction in the pooled P/P and R/P
cell lines was significantly higher than that observed in the R/R
cell lines (Figure 3C).
Conversely, the BDNF inducibility phenotype did not correlate
with the presence of putative risk variants at SNP4 or SNPs 22–
25 at the 30 end of SORL1 (Figures S3A and S3B). Two different
SORL1 primer sets and two different housekeeping genes
confirmed our mRNA expression results (Figure S3C). Because
of the small amount of material we can routinely obtain from pu-
rified neurons, we characterized this phenotype primarily at the
mRNA level. However, we analyzed SORL1 protein levels from
representative fibroblast, NSC, and purified neuron genotypes
and found that SORL1 protein induction from fibroblast to
NSC was blunted in R/R cells compared with P/P and R/P cells,
and, in purified neurons treated with BDNF, there was no
apparent increase in SORL1 protein upon treatment in R/R cells
(Figures S3D and S3E).
Interestingly, we also found that cAMP strongly induced
SORL1 expression in neurons, and the average absolute relative
expression level increase for cAMP-treated neurons was signif-
icant (Figure 3D). When each individual was examined, we found
that cAMP treatment induced SORL1 expression above the
baseline from most, but not all, cell lines (Figure 3E; Table 2).Whenwe examined cell lines treatedwith cAMP,we found that
two R/R cell lines did not respond to treatment, whereas two
R/R cell lines did (Figure 3E). cAMP treatment consistently and
robustly induced SORL1 expression in all other cell lines, sug-
gesting heterogeneity in this signaling pathway (Figure 3F; Table
2). We did not find a significant difference in induction of SORL1
expression between the P/P, R/P, or P/P genotypes after cAMP
treatment (Figure 3F; Table 2).
To rule out the possibility that this induction phenotype in
response to BDNF may be due to decreased pluripotency or dif-
ferentiation efficiency, we compared Tra 1–81 and Tra 1–60 in
hIPSC and CD24 labeling after neuronal differentiation and de-
tected no differences in R/R cells (Figures S4A–S4C). Purified
neurons of all genotypes showed significantly increased expres-
sion of Tau mRNA and exhibited an obvious neuronal
morphology compared with NSC lines (Figures S1A and S4D).
Therefore, we concluded that there are no differences in
pluripotency, differentiation capability, or apparent neuronal
phenotype in cells of different SORL1 genotypes. We also tested
purified neurons for expression of the BDNF receptor TrkB and
found no differences in TrkB expression in R/R cells (Figures
S4E and S4F). Taken together, our data suggest that, rather
than controlling basal expression levels, naturally occurring var-
iants in humans in the 50 region of SORL1 modulate expression
induction in response to BDNF exposure.
Induction of SORL1 Expression Correlates with
Decreased Ab Peptide Production
APP undergoes two cleavage events, by b and g secretases, to
generate the potentially neurotoxic Ab peptide and other frag-
ments. Previous work suggests that SORL1 serves a protectiveCell Stem Cell 16, 373–385, April 2, 2015 ª2015 Elsevier Inc. 377
Figure 3. SORL1 Expression Induction by
the Neurotrophin BDNF Is Dependent on a
Haplotype Associated with Protection from
SAD, and SORL1 Expression Induction by
cAMP Is Independent of This Haplotype
(A) SORL1 induction was tested in response to
BDNF treatment (50 ng/ml) of purified neurons
differentiated from 13 NSC lines. The average
relative expression across all cell lines by qRT-
PCR analysis of purified neuron samples treated
with BDNF from 13 patients shows no significant
induction of SORL1 expression with treatment.
Statistics: Mann-Whitney test, baseline versus
BDNF, p = 0.16.
(B) qRT-PCR analysis of purified neurons derived
from each individual cell line treated with BDNF
shows that all but four cell lines induce SORL1
expression upon treatment. Statistics: t tests
within each cell line, NS, not significant, *p < 0.05,
**p < 0.01.
(C) Analysis of SORL1 expression levels in
response to BDNF treatment when samples are
grouped by variant haplotype at the 50 end of
SORL1. The fold change of SORL1 expression
was calculated between non-treated (NT) and
BDNF-treated samples within the genotype and
reveals that neurons with protective alleles (P/P
and R/P) induce SORL1 in response to BDNF,
whereas R/R cells do not. Statistics: Mann-Whit-
ney test was used to compare P/P and R/P versus
R/R carriers (p = 0.003; P/P, n = 3; R/P, n = 6; R/R,
n = 4. See also Figures S3A–S3E.
(D) SORL1 induction was tested in response to
cAMP treatment (250 mg/ml) of purified human
neurons differentiated from 13 NSC lines. The
average of qRT-PCR analysis of purified neuron
samples treated with cAMP shows a significant
induction of SORL1 expression with treatment.
Statistics: Mann-Whitney test, baseline versus
cAMP, p = 0.02.
(E) qRT-PCR analysis of purified neurons
derived from each individual cell line treated
with cAMP shows that all but two cell lines
induce SORL1 expression upon treatment.
Statistics: t tests within each cell line, *p < 0.05,
**p < 0.01.
(F) Analysis of SORL1 expression levels in response to cAMP treatment when samples are grouped by variant haplotype at the 50 end of SORL1. The fold change
of SORL1 expression was calculated between NT and cAMP-treated samples within the genotype and reveals no difference in SORL1 expression induction
between genotypes. Statistics: Mann-Whitney test was used to compare P/P and R/P versus R/R carriers (p = 0.075; P/P, n = 3; R/P, n = 6; R/R, n = 4).
All error bars are SD.function by binding full-length APP and either sorting it away
from amyloidogenic b and g secretase cleavage pathways or
masking the secretase binding site (Andersen et al., 2005; Her-
mey, 2009; Schmidt et al., 2012). In particular, reducing SORL1
expression in mice and non-neuronal cell lines increases the
production of Ab peptides, whereas induction of SORL1 expres-
sion lowers the production of Ab (Dodson et al., 2008; Rogaeva
et al., 2007; Rohe et al., 2009). Because the amount of Ab pep-
tide produced in the human brain is an important SAD pheno-
type that is potentially related to the cause or progression of
SAD, we tested whether induction of SORL1 with BDNF or
cAMP in purified human neurons had an effect on Ab production
and secretion. Measurement of the average absolute levels of
Ab140 peptides in all cell lines revealed no significant differ-378 Cell Stem Cell 16, 373–385, April 2, 2015 ª2015 Elsevier Inc.ences between cells treated with BDNF or untreated cells (Fig-
ure 4A). However, a clear trend emerged when we evaluated the
fold reduction in Ab140 peptides in each individual line in
response to BDNF treatment. The neurons from the four hIPSC
lines carrying the R/R genomes that did not induce SORL1
expression also did not significantly reduce Ab peptides in
response to BDNF treatment, whereas all neurons from hIPSC
lines carrying R/P or P/P genomes significantly reduced Ab
levels, with the exception of one line, SAD4 (Figure 4B;
Table 2). When analyzed together, the reduction of Ab140 in
all genomes with a P allele versus R/R genomes was significant
(Figure 4C). As published previously (Israel et al., 2012), in some
cell lines Ab1–42 is below the detection range of our assay
because, in our system, endogenous levels of this analyte are
Table 2. Summary of Findings on SORL1 Expression Induction and APP Processing after BDNF or cAMP Treatment in Human Neurons
SORL1
Expression Individual Genotype
Average Fold
Change in SORL1
Expression
Induced by BDNF SD
Inducibility
Phenotype
Average Fold
Change in SORL1
Expression Induced
by cAMP SD
Inducibility
Phenotype
SAD2 P/P 1.52 0.007 inducible 1.84 0.29 inducible
NDC5 P/P 1.45 0.07 inducible 2.64 0.06 inducible
SAD6 P/P 1.49 0.12 inducible 1.53 0.29 inducible
NDC4 R/P 1.81 0.33 inducible 3.57 0.39 inducible
SAD4 R/P 1.41 0.14 inducible 2.23 0.57 inducible
SAD5 R/P 1.70 0.16 inducible 1.52 0.09 inducible
SAD7 R/P 1.51 0.11 inducible 1.72 0.12 inducible
NDC3 R/P 1.79 0.09 inducible 1.91 0.27 inducible
NDC1 R/P 2.09 0.13 inducible 2.01 0.57 inducible
SAD1 R/R 1.19 0.22 non-inducible 1.30 0.11 non-Inducible
CV R/R 1.03 0.41 non-inducible 1.17 0.16 non-inducible
NDC2 R/R 0.80 0.07 non-inducible 1.87 0.09 inducible
SAD3 R/R 1.22 0.09 non-inducible 1.57 0.07 inducible
APP
Processing Individual Genotype
Average Fold
Change in Ab
Levels after
BDNF
Treatment SD
R Than 10%
Decrease in
Ab Peptides
Average Fold
Change in Ab
Levels after
cAMP
Treatment SD
R Than 10%
Decrease in
Ab Peptides
Average Fold
Ab Change
+BDNF
+SORL1
shRNA
Average Fold
Ab Change
+cAMP
+SORL1
shRNA
SAD2 P/P 0.64 0.004 yes 0.34 0.003 yes 0.83 0.41
NDC5 P/P 0.74 0.01 yes 0.56 0.002 yes 0.87 0.49
SAD6 P/P 0.82 0.12 yes 0.38 0.01 yes 0.99 0.41
NDC4 R/P 0.76 0.04 yes 0.49 0.04 yes 0.99 0.54
SAD4 R/P 0.91 0.02 no 0.38 0.03 yes 0.95 0.44
SAD5 R/P 0.74 0.003 yes 0.49 0.02 yes 0.87 0.46
SAD7 R/P 0.82 0.04 yes 0.58 0.08 yes 0.95 0.65
NDC3 R/P 0.74 0.01 yes 0.44 0.005 yes 0.99 0.34
NDC1 R/P 0.86 0.06 yes 0.52 0.003 yes 0.91 0.60
SAD1 R/R 0.91 0.03 no 0.44 0.02 yes 0.99 0.58
CV R/R 0.99 0.05 no 0.54 0.01 yes 0.99 0.62
NDC2 R/R 0.98 0.07 no 0.58 0.01 yes 0.99 0.55
SAD3 R/R 1.05 0.12 no 0.59 0.01 yes 0.82 0.47
13 patient hIPSC cell lines were differentiated to generate purified neurons. The following tests were performed:
(1) SORL1 mRNA expression induction with BDNF or cAMP treatment. The fold induction of SORL1 was analyzed by non-parametric Mann-Whitney
test. For BDNF treatment, P/P and R/P versus R/R, p = 0.003. For cAMP treatment, P/P and R/P versus R/R, p = 0.075. To test whether the association
of non-inducibility with the R/R genotype was significant for BDNF treatment, we set the phenotypic cutoff for non-inducibility at the statistically sig-
nificant lowest R/P (1.41) value and performed a Fisher’s exact test. The two-tailed p value between inducible and non-inducible is 0.001. For cAMP
treatment, the phenotypic cutoff for non-inducibility was set at the lowest R/P (1.52) value for the Fisher’s exact test. The two-tailed p value between
inducible and non-inducible is 0.08.
(2) Ab1–40 peptides were measured after treatment with BDNF or cAMP. The fold decrease in Ab1–40 production was analyzed by Mann-Whitney test.
For BDNF, P/P and R/P versus R/R, p = 0.006. For cAMP, P/P and R/P versus R/R, p = 0.14.
(3) Ab1–40 peptides were measured after treatment with BDNF or cAMP in the presence of a SORL1 shRNA. The fold decrease in Ab1–40 peptides after
BDNF treatment was significantly elevated in P/P and R/P genotypes but not in R/R genotypes, with SORL1 knockdown as analyzed byMann-Whitney
test: P/P and R/P SCR versus KD, p = 0.008; R/R SCR versus KD, p = 0.5. The fold decrease in Ab1–40 peptides after cAMP treatment was not signif-
icantly different in any genotype with SORL1 knockdown as analyzed by Mann-Whitney test: P/P and R/P SCR versus KD, p = 0.86; R/R SCR versus
KD, p = 0.22.approximately five times lower than Ab1–40 in neuronal media.
However, for some lines where we were able to consistently
detect Ab1–42 peptides, we observed a similar trend as with
Ab1–40 (Figure S5A). Although the decrease in Ab production
induced by BDNF in P/P and R/P genomes is apparentlymodest (20%–30%), it is in line with reasonable expectations
for changes that might influence risk but not direct induction
of disease. For example, aggressive, early-onset FAD can be
caused by a highly penetrant APP duplication that increases
APP expression and Ab production by 50% (Israel et al.,Cell Stem Cell 16, 373–385, April 2, 2015 ª2015 Elsevier Inc. 379
Figure 4. Neurons Responsive to SORL1
Expression Induction Show a Decrease in
Ab Peptides
(A) Ab peptide levels were measured after 24 hr
of exogenous BDNF treatment. When average
absolute values of Ab in neurons from 13 cell
lines were analyzed together, BDNF treatment
did not significantly reduce Ab levels. Statistics:
Mann-Whitney test, baseline versus BDNF,
p = 0.39.
(B) Ab peptide levels measured from purified
neurons from each individual cell line ± BDNF
treatment shows that all cell lines that did induce
SORL1 expression with BDNF treatment, except
SAD4, have a reduction in Ab levels but that there
is no change in Ab peptides in the four cell lines
that did not induce SORL1 expression. Statistics:
t tests within each cell line, *p < 0.05, **p < 0.01.
See also Figure S5A.
(C). Analysis of Ab reduction when samples are
grouped by variant haplotype at the 50 end of
SORL1 in response to BDNF treatment. Neurons
treated with BDNF showed a significant reduc-
tion in Ab peptides in cells with protective alleles
(P/P and R/P). Ab peptide production in cells
homozygous for the risk alleles (R/R) was not
affected by BDNF treatment. Statistics: Mann-
Whitney test was used to compare P/P and R/P
versus R/R (p = 0.006; P/P, n = 3; R/P, n = 6; R/R
n = 4).
(D) Ab peptide levels were measured after 24 hr
of exogenous cAMP treatment. When average
absolute values of Ab in neurons from 13 cell
lines were analyzed together, cAMP treatment
did significantly reduce Ab levels. Statistics:
Mann-Whitney test, baseline versus cAMP,
p = 0.007.
(E) Ab peptide levels from purified neurons from
each individual cell line ± cAMP treatment shows
that all cell lines have a significant reduction in Ab
regardless of whether SORL1 expression was
induced. Statistics: t tests within each cell line,
*p < 0.05, **p < 0.01.
(F) Analysis of Ab reduction when samples are
grouped by variant haplotype at the 50 end of
SORL1 in response to cAMP treatment. Neurons
treated with cAMP showed a reduction in Ab peptides in all genotypes, with no significant differences between neurons with P or R alleles. Statistics: Mann-
Whitney test was used to compare P/P and R/P versus R/R Ab response to cAMP treatment (p = 0.14; P/P, n = 3; R/P, n = 6; R//R, n = 4).
All error bars are SD.2012; Rovelet-Lecrux et al., 2006; Shi et al., 2012). Therefore,
the average 20% change in APP processing we observed
in these in vitro experiments is significant in the context of
SAD risk.
In contrast to BDNF, cAMP treatment significantly and
robustly decreased absolute Ab levels by an average of 50%–
60% in purified neurons of all genotypes (Figures 4D and 4E;
Table 2). This decrease was similar among all genotypes tested,
and there was no significant difference in Ab reduction between
P/P and R/P compared with R/R genomes (Figures 4E and 4F;
Table 2). Taken together with our expression data, these results
suggest that SAD risk associated with SORL1 genomic variants
may be generated via specific signaling pathwayswithin neurons
and that the impact of SORL1 induction may vary in different
genomic backgrounds.380 Cell Stem Cell 16, 373–385, April 2, 2015 ª2015 Elsevier Inc.Decreased Ab Peptides Caused by BDNF, but Not cAMP,
Requires SORL1
To determine whether the reduction of Ab in response to BDNF
or cAMP treatment requires SORL1 expression, we designed
an shRNA against the human SORL1 mRNA and documented
a robust and consistent knockdown of SORL1 mRNA and pro-
tein in transduced purified neurons of all genotypes (Figures
S5B and S5C). We then treated transduced neurons with
BDNF and observed that the decrease in Ab peptides in neurons
with P haplotypes at the SORL1 locus was almost completely
abrogated in neurons expressing the SORL1 small hairpin RNA
(shRNA), whereas knockdown of SORL1 had little effect in cells
with R/R genotypes (Figure 5A; Table 2), suggesting that the
decrease in APP processing after BDNF treatment is dependent
on SORL1. In contrast, SORL1 knockdown neurons treated with
cAMP still exhibited a reduction of Ab peptides (Figure 5B), indi-
cating that, in purified neurons, cAMP regulates pathways in
addition to SORL1 that can impact Ab production independently.
Overexpression of a SORL1 cDNA in BDNF Non-
Responsive Cells Reduces Ab Peptides
Our data corroborate most other work in cell and animal models,
demonstrating that increased SORL1 expression reduces Ab
peptides and raises the possibility of targeting this pathway for
new AD therapies (Caglayan et al., 2014). However, because
SORL1 genetic risk variants may affect pathways that regulate
SORL1 expression, individual patient genotypes may respond
differently to various agents designed to induce SORL1. To
test whether SORL1 activation can be beneficial in neurons
that do not induce expression after BDNF treatment, we stably
overexpressed a SORL1 cDNA in R/R neurons (derived from
J.C.V. hIPSCs). We observed that, after 5 days in culture, the
R/R neurons from J.C.V. containing the SORL1 cDNA showed
a 4-fold increase in SORL1 mRNA, approximately the same
fold induction as the highest cell line induced with cAMP (Fig-
ure 5C). These SORL1-overexpressing neurons had significantly
reduced levels of both Ab40 and 42 peptides when the cells were
harvested after 5 days in culture (Figure 5D).
DISCUSSION
We used hIPSC technology to elucidate molecular phenotypes
associated with naturally occurring, uniquely human variants in
a gene associatedwith SAD risk, SORL1. In particular, the neuro-
trophic growth factors and intracellular signaling molecules
BDNF and cAMP can induce SORL1 expression above the base-
line in some genotypes of human neurons. In the case of BDNF,
only neurons with P/P or R/P genotypes increased SORL1
expression and demonstrated a significant reduction in Ab,
whereas there was no effect in R/R neurons. BDNF-induced
reductions in Ab peptides in P genomes required SORL1 expres-
sion induction, as demonstrated by shRNA experiments,
suggesting that the degree of change in Ab we observed in neu-
rons upon BDNF treatment is dependent on SORL1 action,
whereas cAMP treatment activates other pathways in addition
to SORL1. Finally, we noted that activation of the SORL1
pathway by overexpression of SORL1 cDNA reduces Ab gener-
ation even in neurons whose SORL1 gene is not responsive to
BDNF. The effect of BDNF on SORL1 expression and APP pro-
cessing correlated only with the SORL1 R or P genotypes and
not with whether the hIPSC lines were derived from SAD or con-
trol fibroblasts. This observation is consistent with previous find-
ings showing that SORL1 haplotypes modulate SAD risk with
moderate effect size and is typical of most variants associated
with increased SAD risk, given that the net effects result from
polygenic interactions with many other factors contributing to
the overall risk of developing disease. We propose that BDNF-
induced increases in SORL1 expression in patients harboring
the P haplotype may reduce their risk of developing SAD by
reducing amyloidogenic processing of APP in their neurons.
However, the different responses of purified neurons to BDNF
versus cAMP also suggest that genomic variants impact specific
intracellular signaling pathways and should be considered when
designing potential therapeutics, which can be tested using anhIPSC system that captures individual genetic backgrounds in
a dish (Figure 5E).
As observed in our sample, the 50 8, 9, and 10 SNPs are almost
always reported as a haplotype block in northern andwestern Eu-
ropeanpopulationsamples (Figure 1B;Reitzet al., 2011;Rogaeva
et al., 2007). These variants, along with others in the gene, have
been associated with a number of potentially relevant endophe-
notypes (reviewed in Reitz, 2012). SNPs 8, 9, and 10were in com-
plete linkage disequilibrium in our sample and were in complete
disequilibrium with the cellular phenotype defined by the SORL1
response to BDNF. Although the sample size was small, we sug-
gest thatwehave identifieda relevant upstreamphenotypic effect
behind consistent findings of genotypic association with clinical
SAD. Consistent with our expression-related phenotype, neigh-
boring 50 SORL1 SNPs predicted a 2-fold difference in the
SORL1 mRNA level in the temporal cortex (McCarthy et al.,
2012). Although this study did not probe the exact 8, 9, and 10
loci, it examined the same genomic interval, which is in strong
LD and supports the hypothesis that genetically determined
expression levels are behind the 50 SORL1-AD association.
Recently there have been several reports of rare, causative,
single-nucleotide variants in the coding region of SORL1 that
are associated with early-onset familial AD (Pottier et al., 2012)
and late-onset AD (Vardarajan et al., 2015). Although our study
and those of others (Grear et al., 2009; McCarthy et al., 2012)
point to the 50 region of SORL1 as a potentially important region
in the regulation of SORL1 gene expression, the 8, 9, 10 SNPs
mark a haplotype and are not necessarily causative variants.
Genome editing in hIPSCs has been used successfully to intro-
duce dominant mutations in several neurodegenerative disease
models, including AD (Li et al., 2013; Soldner et al., 2011;
Woodruff et al., 2013), and is a powerful technique to elucidate
molecular phenotypes caused by these variants. However,
most isogenic lines derived so far harbor single point mutants,
and careful dissection of large haplotype blocks is a significant
technical challenge. Important future work should involve
dissection of the entire haplotype block using genome editing
to more precisely identify the nucleotide variant(s) that is/are
important for the regulation of SORL1 expression by BDNF.
Our work on SORL1 corroborates most previous studies in cell
and animal models (Andersen et al., 2005; Caglayan et al., 2014;
Rogaeva et al., 2007; Rohe et al., 2009) and reiterates that SORL1
is an important player inSADbiology. However, our data highlight
some important differences betweenmouse and human systems
and underscores the unique and novel applications of hIPSC
technology to investigate disease-associated genes. First, by
capturing an individual patient’s unique genetic background in
a hIPSC line, we are able to examine genetic variants that are
either not present or do not have the same effect in the mouse
genome. Second, our data reveal that, in living cell types relevant
to human neurodegenerative disease, expression, and response
of SORL1 to stimulation is highly variable, and the phenotypic
readout is different depending on the genetic backgrounds. Our
study is distinct fromother hIPSCmodels, demonstrating pheno-
types of highly penetrant genetic variants that deterministically
cause disease and in which the described phenotype is corre-
lated with the disease state. Instead, we suggest that we have
demonstrated the potential effects of a risk factor, not a pene-
trant, hereditary mutation. The fact that the genetic variant andCell Stem Cell 16, 373–385, April 2, 2015 ª2015 Elsevier Inc. 381
Figure 5. SORL1 Is Required for Ab Reduction in Neurons Treated with BDNF but Not cAMP, and Overexpression of SORL1 Decreases Ab
Production in a BDNF Non-responsive Cell Line
(A) Neurons were transduced with a lentivirus containing either a SORL1 scrambled (SCR) shRNA () or a SORL1 knockdown (KD) shRNA (+) and treated with
exogenous BDNF (+) for 24 hr. In BDNF-responsive neuronswith P alleles, the presence of a SORL1 shRNA significantly reduced the decrease in Ab peptideswith
BDNF treatment. Statistics: Mann-Whitney test was used to compare SCR versus KD for BDNF treatment (P/P and R/P SCR versus KD, p = 0.008; R/R SCR
(legend continued on next page)
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associated cellular phenotype we have described is not corre-
lated with the clinical disease state is, in fact, important when
thinking about SAD. Each individual human harbors factors in
his or her genome that predispose to or protect from SAD. How
these factors interact with each other and the environment is un-
known. Interestingly, two of the R/R individuals in this study are
classified as NDC and are over the age of 65 with no clinically
apparent signs of cognitive impairment. In the case of these
individuals, we speculate that other protective factors in their
genome may overcome possible gene expression defects in
SORL1 and prevent disease. Similarly, two of the P/P individuals,
whose hIPSC-derived neurons responded significantly to BDNF-
induced SORL1 expression and reduction of Ab, were diagnosed
with probable SAD, indicating that these individuals may harbor
variants at other loci that enhance the SAD risk by other mecha-
nisms. These observations in our data are consistent with the
pattern of low clinical penetrance expected for most SAD risk
alleles (Bertram et al., 2007; Chouraki and Seshadri, 2014)
Because the hIPSC field progresses rapidly andmore lines are
generated from patients, we propose that an important future
step in the field will be to use hIPSCs to understand the biology
in human neurons and glia driven by the genes identified as risk
factors. In addition to elucidating important biological pathways
behind hits identified in GWASs, these studies will also drive the
development of individualized treatments because risk factors
may identify which patients are viable candidates for a specific
drug or would preferentially participate in, or be excluded from,
certain clinical trials. Progress in this area is vital to developing
SAD treatments in particular because SAD may well be a func-
tion of a variety of phenotypes driven by different genetic factors
and primary phenotypic lesions. Our work provides an important
first advance in understanding how individual human genomes
and specific genomic haplotypes might generate neuronal phe-
notypes and which factors might contribute to SAD in individual
patients and provide concrete insights into how stem cell tech-
nology can drive an understanding of personalized medicine
and clinical trial design in AD and beyond.
EXPERIMENTAL PROCEDURES
hIPSC, NSCs, and Neuron Generation and Characterization
All hIPSC lines were generated by four-factor reprogramming (Gore et al.,
2011; Israel et al., 2012). hIPSC lines were maintained on a mouse embryonicversus KD, p = 0.5; P/P, n = 3; R/P, n = 6; R/R, n = 4). Between genotypes, there w
SORL1 shRNA and treated with BDNF (white bars, P/P and R/P versus R/R, p =
(B) Neuronswere transducedwith a lentivirus containing either a SORL1 SCR shRN
In all neurons there was a reduction in Ab peptide production upon treatment with
Whitney test was used to compare SCR versus KD cAMP treatment (P/P and R/P S
R, n = 4). Between genotypes, there was no statistical difference in Ab peptides in
(C) J.C.V. neurons stably expressing either empty vector or a SORL1 cDNA we
expression in stable SORL1-overexpressing neurons was compared to vector alo
SORL1 expression.
(D) Ab140&42 peptides were measured from the medium of J.C.V. neurons stably
in Ab peptides was calculated between vector only and SORL1 cDNA-expressin
**p < 0.01.
(E) Summary of findings regarding SORL1 expression in human purified neurons
variants analyzed in this study. Neurons with P variants have increased SORL1 ex
lead to reduced AD risk. Neurons with the R/R haplotype have no change in SO
increasing the risk for developing AD. However, alternative methods to induce SO
a viable strategy for individuals harboring risk variants and can be tested on varifibroblast (MEF) feeder layer in HUES medium (Israel et al., 2012) and were
routinely tested for mycoplasma. For RNA/DNA analysis, cells were trans-
ferred from MEFs to Matrigel, cultured in MEF-conditioned HUES medium,
and maintained for several passages before harvesting. For germ layer differ-
entiation analyses, embryoid bodies (EBs) were generated by growing hIPSC
in low-adherence plates for 14 days without fibroblast growth factor (FGF) with
a medium change every other day. Previously published hIPSC lines were
cytogenetically karyotyped (Cell Line Genetics), whereas unpublished hIPSC
lines were karyotyped digitally by hybridization to the Illumina InfiniumHuman-
CoreExomeBeadChip module version 1.9.4. Pluripotency gene expression in
published lines has been described previously (Gore et al., 2011; Israel
et al., 2012). Unpublished lines were analyzed for pluripotency by fluores-
cence-activated cell sorting (FACS) for the cell surface antigens Tra 1–81
and Tra 1–60 (BD Biosciences). The differentiation capability of published lines
has been described previously (Israel et al., 2012). For unpublished lines, RNA
from EBs and parent hIPSC lines was harvested and converted to cDNA
(Superscript, Invitrogen). qRT-PCR was performed with a primer specific for
endoderm (AFP), mesoderm (DCN), and ectoderm/neuroectoderm (COL1A1,
NEST). NSCs and neurons were generated using protocols described previ-
ously (Israel et al., 2012; Yuan et al., 2011) and purified by FACS. NSCs
were stained for Nestin (Millipore), and neurons were stained for MAP2 (Milli-
pore). For each genotype, neurons derived from at least two independent
hIPSC lines were examined.
Cell Culture, Experimental Design, and Sample Collection
NSCsweremaintained in DMEMF12medium supplementedwith B27, N2, and
Fgf (20 ng/ml) and were routinely tested for mycoplasma. NSCs were differen-
tiated to neurons by Fgf withdrawal and cultured in the presence of BDNF, glial
cell line-derived neurotrophic factor, anddibutyryl cAMP (dbcAMP) for 3weeks
as described previously (Israel et al., 2012; Yuan et al., 2011). Purified neurons
were generated by FACS using a published cell surface signature (Yuan et al.,
2011). Neurons were plated in biological replicates treated as described in the
figure legends and harvested for RNA or protein. All qRT-PCR samples were
run in triplicate. SORL1 expression experiments and analyses in purified neu-
rons are reported in the figure legends in terms of the 13 individual patient
genomes analyzed. However, for each genotype (P/P, R/P, or R/R), neurons
derived from at least two independent hIPSC lines were examined. SORL1
expression experiments and analyses were repeated in all genotypes for a
minimum of two independent differentiations and, for some genotype repre-
sentative cell lines (SAD1 [P/P], NDC1 [R/P], and CV [R/R]), four or more times.
SORL1 SNP Genotyping
Genotyped SNPs were identified from Rogaeva et al. (2007) and are listed in
Figure 1.
Fibroblast cultures from each patient were lysed, and genomic DNA
was isolated using the DNeasy kit (QIAGEN). Allele-specific primers for the
SNPs analyzed were designed using the Web-based allele-specific primer-
designing tool (http://bioinfo.biotec.or.th/WASP). PCR were run using Hot-
Star Polymerase (QIAGEN) and analyzed by agarose gel electrophoresis. Aas no statistical difference in Ab peptides among all lines transduced with the
0.19). See also Figures S5B and S5C.
A () or a SORL1KD shRNA (+) and treatedwith exogenous cAMP (+) for 24 hr.
cAMP that was not significantly altered by the SORL1 shRNA. Statistics: Mann-
CR versus KD, p = 0.86; R/R SCR versus KD, p = 0.22; P/P, n = 3; R/P, n = 6; R/
all lines transduced with the SORL1 shRNA (P/P and R/P versus R/R, p = 0.29).
re generated using the PiggyBac system, and qRT-PCR analysis of SORL1
ne. SORL1-overexpressing neurons show an approximately 4-fold increase in
expressing either empty vector or a SORL1 cDNA after 5 days. The fold change
g neurons. Statistics: paired t test comparing vector alone with SORL1 cDNA,
. The schematic depicts only the region of the SORL1 gene containing the 50
pression with BDNF treatment, resulting in reduced Ab production, which may
RL1 expression or Ab production with BDNF treatment, therefore potentially
RL1 expression that do not involve BDNF signal transduction pathways may be
ous genetic backgrounds using hIPSC technology.
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list of all allele-specific primers used in this study is provided in the Supple-
mental Experimental Procedures.
Expression Analyses
SORL1 expression was analyzed by measuring mRNA and protein. For
mRNA, total RNA from triplicate cell culture experiments was isolated using
the RNeasy kit (QIAGEN) and DNase-treated (Ambion). cDNA was tran-
scribed from total RNA using the Superscript first-strand system (Invitro-
gen). qRT-PCR was performed using FastStart SyBr Green (Roche) and
samples were run on an Applied Biosystems 7300 real-time PCR system.
RT-PCR primers for all genes in this study were designed using Primer3
and spanned intron-exon boundaries. A list of all primers is provided in
the Supplemental Experimental Procedures. qRT-PCR data were analyzed
using the DDCt method and normalized to housekeeping genes TBP or
RPL27, as noted in the figure legends. For protein, cells were lysed in 1%
NP40 or radioimmunoprecipitation assay (RIPA) buffer. Protein concentra-
tion was determined using either Bradford (Bio-Rad) or bicinchoninic acid
(BCA) (Pierce) assays. Protein lysates were run on NuPAGE 4%–12% Bis-
Tris gels (Invitrogen), transferred to nitrocellulose membranes, and probed
with antibodies to either SORL1 (BD Biosciences, clone 48/LR11) or Actin
(Millipore). Quantification of the western blots was performed using ImageJ
software.
BDNF and cAMP Treatment
For purified neurons, triplicate cell culture experiments were treated with
BDNF (PeproTech, 50 ng/ml) or dbcAMP (Sigma, 250 mg/ml) for 24 hr. After
24 hr, cells were harvested for RNA using the RNeasy kit (QIAGEN) or protein
using either 1% NP40 or RIPA buffer. Data represent at least two independent
differentiation experiments.
AbMeasurements
Purified neurons were seeded at 200,000 cells/well of a 96-well plate.
After 5 days in culture, medium was harvested from triplicate wells and
run on an Ab Triplex ELISA plate (Meso Scale Discovery). Corresponding
wells were lysed with RIPA buffer, and protein concentration was determined
by BCA assay (Pierce). Ab levels were normalized to the amount of total
protein.
Statistics
Based on examination of distribution assumptions, t tests were used for
within-cell line comparisons of expression levels before and after neurotro-
phin treatment, but otherwise all analyses were performed using non-para-
metric statistical tests. These tests are more conservative and less powerful
that parametric ANOVA and t tests but are robust to normality assumptions
and, therefore, not prone to spurious type I errors. Between-genotype
differences in continuous variables were analyzed by Kruskal-Wallis test, as
stated in the figure legends. Two group comparisons of pooled P/P and
R/P cells lines to R/R cell lines were tested using non-parametric Mann-Whit-
ney tests, as stated in the figure legends. The distribution of categorical
outcomes across genotype groups was compared using Fisher’s exact test.
All testing was two-sided and was performed using the R statistical program-
ming language (R Development Core Team, 2008). All statistical results were
verified independently using the VassarStats computational website (http://
vassarstats.net/).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and two tables and can be found with this article online at http://
dx.doi.org/10.1016/j.stem.2015.02.004.
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